0
0
New Delhi – In a significant development for cancer care in India, the Indian Council of Medical Research (ICMR) has announced funding for a pioneering nationwide clinical trial aimed at making targeted ovarian cancer treatment more affordable and accessible. The trial, titled IPIROC (Intermittent PARP Inhibitor Regimen in Ovarian Cancer), will evaluate whether a “twice-weekly” dosing schedule of the drug rucaparib is as effective as the standard daily regimen, potentially slashing treatment costs by nearly 75% and reducing debilitating side effects.
A Critical Intervention for Indian Healthcare
Ovarian cancer remains a formidable health challenge in India, ranking as the third most common cancer among women, with approximately 47,000 new cases and nearly 33,000 deaths reported annually, according to GLOBOCAN 2022 data. While targeted therapies like PARP (Poly ADP-ribose Polymerase) inhibitors have revolutionized survival rates for patients—particularly those with BRCA gene mutations—their prohibitive cost and severe toxicity profile have limited their widespread use in low-and-middle-income countries (LMICs).
The standard protocol for PARP inhibitors involves daily oral intake, which can cost patients anywhere between ₹20,000 to ₹45,000 per month depending on the brand. This financial burden, coupled with side effects like severe anemia, fatigue, and nausea, forces many women to discontinue the life-extending therapy prematurely.
The IPIROC trial, led by the Kolkata Gynaecological Oncology Trials and Translational Research Group (KOLGOTRG), seeks to challenge the “more is better” paradigm of cancer dosing.
The Science: Why “Less” Might Be Enough
The trial is spearheaded by Dr. Asima Mukhopadhyay, a renowned clinician-scientist and Director of KOLGOTRG. The study is built on robust pre-clinical evidence suggesting that the biological effect of rucaparib persists long after the drug leaves the bloodstream.
“Laboratory studies have shown that a single dose of the PARP inhibitor rucaparib can inhibit the PARP enzyme for more than 72 hours,” explained Dr. Mukhopadhyay at the trial’s launch. “This provides a proof-of-concept that daily dosing—which is based on maximum tolerated limits rather than biological necessity—may be overkill for many patients.”
By switching to a twice-weekly schedule, the study aims to achieve three critical goals:
-
Maintain Clinical Efficacy: Ensure the drug continues to effectively kill cancer cells by blocking DNA repair.
-
Reduce Toxicity: Lower the incidence of blood-related side effects like anemia, which often necessitate blood transfusions or treatment pauses.
-
Cut Costs: An intermittent schedule could reduce the monthly cost of the drug to roughly one-fourth of the current standard, making it viable for thousands of uninsured families.
Global Collaboration and Support
The launch of the IPIROC trial coincides with the publication of The Every Woman Study: Low- and Middle-Income Country Edition in The Lancet, which highlights the glaring global disparities in access to cancer care.
The trial was officially launched at KOLGOTRG’s 8th annual meeting in Kolkata, attended by global heavyweights in oncology, including Dr. Michael Bookman, Chair of the Gynaecological Cancer Intergroup (GCIG), and Dr. Amit Oza, past Chair of GCIG. Their presence underscores the international significance of this Indian-led initiative.
The study represents a unique “academia-industry” partnership. While ICMR provides the primary research funding, Suraksha Clinic and Diagnostics Limited is facilitating the infrastructure, including biobanking and advanced biomarker testing. Additionally, pharmaceutical support will ensure eligible patients enrolled in the trial receive the costly drug free of charge.
Implications for Patients and Public Health
If successful, the IPIROC trial could fundamentally change the standard of care not just in India, but globally for resource-constrained settings.
“High costs and treatment-related toxicities often force patients to discontinue PARP inhibitors,” Dr. Mukhopadhyay noted. “Through this study, we aim to identify the right dose for the right patient, while making cutting-edge treatment more affordable and accessible.”
For the average patient, this research offers hope that financial status will no longer dictate their ability to fight cancer. Moving from a daily pill to a twice-weekly regimen would not only save families lakhs of rupees annually but also significantly improve the patient’s quality of life by reducing the physical toll of the medication.
Challenges and The Road Ahead
While the hypothesis is promising, the trial must prove that the lower dose does not compromise survival outcomes. Clinical trials take time, and results will need to be rigorously peer-reviewed before clinical guidelines can change. Furthermore, widespread implementation will require buy-in from oncologists who are accustomed to standard global protocols.
However, the medical community remains optimistic. By focusing on “cost-effective dosing,” India is taking a lead in frugal innovation—finding smarter, scientifically sound ways to deliver high-quality healthcare to the masses.
Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
-
Primary News Source: “ICMR Funds Pan-India Clinical Trial to Test Cost-Effective Dosing of PARP Inhibitor in Ovarian Cancer.” ETHealthworld, December 15, 2025.
